ADVANCE_HTA

Advancing and strengthening the methodological tools and practices relating to the application and implementation of Health Technology Assessment (HTA)

 Coordinatore LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE 

 Organization address address: Houghton Street 1
city: LONDON
postcode: WC2A 2AE

contact info
Titolo: Ms.
Nome: Milena
Cognome: Vasileva
Email: send email
Telefono: +44 20 7852 3604
Fax: +44 20 7955 6187

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 4˙035˙099 €
 EC contributo 2˙999˙805 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-01-01   -   2015-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE

 Organization address address: Houghton Street 1
city: LONDON
postcode: WC2A 2AE

contact info
Titolo: Ms.
Nome: Milena
Cognome: Vasileva
Email: send email
Telefono: +44 20 7852 3604
Fax: +44 20 7955 6187

UK (LONDON) coordinator 825˙355.95
2    TECHNISCHE UNIVERSITAT BERLIN

 Organization address address: STRASSE DES 17 JUNI 135
city: BERLIN
postcode: 10623

contact info
Titolo: Mrs.
Nome: Silke
Cognome: Hönert
Email: send email
Telefono: +49 30 314 79973
Fax: +49 30 314 21689

DE (BERLIN) participant 422˙080.00
3    ESCUELA ANDALUZA DE SALUD PUBLICA SA

 Organization address address: CUESTA DEL OBSERVATORIO CAMPUS UNIVERSITARIO CARTUJA 4
city: GRANADA
postcode: 18010

contact info
Titolo: Mr.
Nome: Jose
Cognome: Cuellar Hurtado
Email: send email
Telefono: 34958027400

ES (GRANADA) participant 282˙094.20
4    UNIVERSIDAD DE CASTILLA - LA MANCHA

 Organization address address: CALLE ALTAGRACIA 50
city: CIUDAD REAL
postcode: 13071

contact info
Titolo: Ms.
Nome: Maria Llanos
Cognome: Carrion Varela
Email: send email
Telefono: +34 967 599354
Fax: +34 967 599305

ES (CIUDAD REAL) participant 261˙760.00
5    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

 Organization address address: KEPPEL STREET
city: LONDON
postcode: WC1E7HT

contact info
Titolo: Prof.
Nome: John Alexander
Cognome: Cairns
Email: send email
Telefono: +44 2079272395

UK (LONDON) participant 233˙640.00
6    ISTITUTO SUPERIORE DI SANITA

 Organization address address: Viale Regina Elena 299
city: ROMA
postcode: 161

contact info
Titolo: Dr.
Nome: Rosa Maria
Cognome: Martoccia
Email: send email
Telefono: +39 06 49902688
Fax: +39 06 49903007

IT (ROMA) participant 198˙000.00
7    INSTITUT ZA EKONOMSKA RAZISKOVANJA

 Organization address address: Kardeljeva ploscad 17
city: LJUBLJANA
postcode: 1000

contact info
Titolo: Dr.
Nome: Boris
Cognome: Majcen
Email: send email
Telefono: +386 1 5303810

SI (LJUBLJANA) participant 192˙960.00
8    PAN AMERICAN HEALTH ORGANIZATION

 Organization address address: 23RD STREET NW 525
city: WASHINGTON DC
postcode: 20037

contact info
Titolo: Mr.
Nome: Ian
Cognome: Stein
Email: send email
Telefono: +1 202 974 3198

US (WASHINGTON DC) participant 175˙947.20
9    NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

 Organization address address: "MidCity Place, High Holborn 71"
city: LONDON
postcode: WC1V 6NA

contact info
Titolo: Dr.
Nome: Kalipso
Cognome: Chalkidou
Email: send email
Telefono: 447787000000

UK (LONDON) participant 146˙617.25
10    THE EUROPEAN BRAIN COUNCIL AISBL

 Organization address address: rue d'Egmont 11
city: BRUXELLES
postcode: 1000

contact info
Titolo: Dr.
Nome: Alastair
Cognome: Benbow
Email: send email
Telefono: 447747000000

BE (BRUXELLES) participant 98˙760.00
11    UNIVERSITE PARIS XII VAL DE MARNE

 Organization address address: AVENUE DU GENERAL DE GAULLE 61
city: CRETEIL
postcode: 94010

contact info
Titolo: Prof.
Nome: Isabelle
Cognome: Durand-Zaleski
Email: send email
Telefono: 33149813674

FR (CRETEIL) participant 77˙120.00
12    AGENCJA OCENY TECHNOLOGII MEDYCZNYCH

 Organization address address: ULICA IGNACEGO KRASIKIEGO 26
city: WARSZAWA
postcode: 02-611

contact info
Titolo: Ms.
Nome: Anna
Cognome: Zawada
Email: send email
Telefono: +48 22 566 72 47

PL (WARSZAWA) participant 56˙160.40
13    TANDVARDS-OCH LAKEMEDELSFORMANSVERKET

 Organization address address: FLEMINGGATAN 7
city: STOCKHOLM
postcode: 10422

contact info
Titolo: Dr.
Nome: Douglas
Cognome: Lundin
Email: send email
Telefono: 46856842700

SE (STOCKHOLM) participant 29˙310.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

community    purpose    allocation    care    eunethta    preferences    decision    drugs    methodological    settings    model    advance    medical    tools    diseases    severity    mcda    adaptable    health    patients    effectiveness    hta    therapy    capacity    ongoing    data    types    risk    evidence    quality    coverage    resource    countries    optimise    wider    http    decisions    analysed    disease    rare    advancements    taxonomy   

 Obiettivo del progetto (Objective)

'The use of HTA has increased recently in Europe and more widely (e.g. Americas) to enable evidence-based coverage decisions and improve efficiency in resource allocation. HTA has often resulted in different coverage decisions across settings despite the same evidence being used for this purpose. This may reflect in part societal preferences about value, priorities or risk perceptions, suggesting a significant need for methodological improvements and extensions. The fundamental objective of ADVANCE_HTA is to contribute to advancements in the methods for HTA in European and other settings by involving the wider stakeholder community in areas actively and heavily debated given their implications for decision-making and resource allocation, as follows: • First, the issue around value for money and the different approaches surrounding current thresholds for resource allocation; • Second, the concept of value assessment, and the factors that need to be considered beyond cost effectiveness, such as disease severity; • Third, to improve the quality of the evidence required for and the methods associated with the assessment of rare diseases; • Fourth, to advance the debate in the elicitation of preferences by deriving these in more realistic settings within the patient community in the wider EU; • Fifth, to advance the debate on the suitability of current HTA tools across different categories of medical devices (e.g. diagnostics); and • Sixth, to improve the implementation and capacity building of HTA including outside Europe, where HTA is considered explicitly in decision-making. ADVANCE_HTA aims to broaden the spectrum, complement and address areas of intense methodological debate in the application, use and implementation of HTA. It also aims to improve HTA methods, which can be taken further by competent authorities nationally whilst supplementing the work of supra-national bodies (e.g. EUnetHTA) towards a common understanding of choices in health care decision-making.'

Introduzione (Teaser)

Scientific and technological advancements in the health care sector make decision making a complex endeavour. As a result, use of health technology assessment (HTA) tools to optimise resource allocation in health care settings is steadily increasing.

Descrizione progetto (Article)

The EU-funded http://www.advance-hta.eu (ADVANCE_HTA) project is working on improving HTA methodologies, broadening its scope and relevance for better implementation in various types of health care systems. Efforts will be made to obtain inputs from all stakeholders, starting from decision makers and ending with patients.

Areas of research include factors such as cost-benefit, cost effectiveness, burden of disease and disease severity. Data and methodologies will be analysed using decision analytic frameworks such as discrete choice experiments (DCEs) and multiple-criteria decision analysis (MCDA).

HTA systems of 15 EU countries were comprehensively analysed and a taxonomy of important variables was developed. This taxonomy has been applied to four countries so far for cancer disease and work is ongoing to construct an econometric model for analysis.

Systematic country-specific literature reviews were carried out to assess HTA decisions across different types of drugs, therapy areas and countries. Besides determining differences in how health technology is valued, this should help in developing an MCDA-based methodological framework that is adaptable to any health care system.

Emphasis was placed on understanding and optimising HTA decision making with regard to rare diseases. For this purpose, ADVANCE_HTA forged strong links with other European initiatives associated with rare diseases, such as BURQOL-RD, EPIRARE and http://www.eunethta.eu/ (EUNetHTA). Data on 10 orphan drugs from 4 countries was analysed to quantify the socioeconomic costs and health-related quality of life of such patients. As a result, a DCE survey was modelled and is currently being pilot tested.

ADVANCE_HTA developed a taxonomic model for HTA on medical devices incorporating factors such as risk and functionality. Data collection on capacity and HTA decision-making processes is currently ongoing to better support HTA implementation. Surveys were sent to 41 countries in Central and Eastern Europe and in Latin America and are currently being piloted in 5 Caribbean countries.

ADVANCE_HTA activities should help identify evidence gaps and facilitate development of robust and adaptable HTA methodologies to guide policies, future research agenda and best practices. This should optimise resource allocation and ensure health system sustainability irrespective of system- or therapy-specific HTA-based decisions.

Altri progetti dello stesso programma (FP7-HEALTH)

SYSCILIA (2010)

A systems biology approach to dissect cilia function and its disruption in human genetic disease

Read More  

ALLFUN (2010)

"Fungi in the setting of inflammation, allergy and autoimmune diseases:Translating basic science into clinical practices"

Read More  

SYSVASC (2014)

Systems Biology to Identify Molecular Targets for Vascular Disease Treatment

Read More